“Enveric Biosciences, Inc.”

Company description: “Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Leveraging its unique discovery and development platform, The Psybrary™, Enveric has created a robust Intellectual Property portfolio of New Chemical Entities for specific mental health indications. Enveric’s lead program, the EVM201 Series, comprises next generation synthetic prodrugs of the active metabolite, psilocin. Enveric is developing the first product from the EVM201 Series – EB-373 – for the treatment of anxiety disorders. Enveric is also advancing its second program, the EVM301 Series, to offer a first-in-class, new approach to the treatment of difficult-to-address mental health disorders, mediated by the promotion of neuroplasticity without also inducing hallucinations in the patient. Enveric is headquartered in Naples, FL with offices in Cambridge, MA and Calgary, AB Canada.”

Business Data

Company slogan: A New Approach to Solving Mental Health Challenges

Headquarters: “Cambridge, MA”

Employees: 15

Ownership type: Public

Year founded: 2020

Specializations: “Drug Discovery, Pharmaceuticals, Patents, Intellectual Property, Biotechnology, Mental Health, Neuroplasticity, and Life Sciences”


Social Media

Linkedin: https://www.linkedin.com/company/envericbio

Facebook: https://www.facebook.com/EnvericBiosciences

Youtube: https://www.youtube.com/watch?v=p4Etar8IEtk


Twitter: https://twitter.com/Enveric_Bio


Marketing Data

Website: https://enveric.com/

Website title: Enveric Biosciences

Website description: none


Referring domains: 232

Website pages indexed: 408

Languages: English